We provide commercially focused, creative advice on obtaining, enforcing and exploiting intellectual property rights including patents, trade marks and designs to a wide range of clients who enjoy our straight forward approach and flexible working practices.
From its small beginnings in 1867, Mewburn Ellis has grown into a vibrant, outward-looking partnership with innovation at its core. As science and technology continue to transform the way we live, we look forward to a future as positive and successful as our past.
It's business as usual for Mewburn Ellis despite the decision for the UK to end its membership of the EU. We consider the effect of the decision on intellectual property.
The Unitary Patent (UP) and Unified Patent Court (UPC) are due to come into entry in the near future and aim to bring a single patent right and single patent litigation forum to Europe.
With a medtech team including patent attorneys drawn from all technical disciplines, you can rest assured that you will be working with a specialist that truly understands your technology.
The worldwide recognition achieved by our large pharmaceutical team will give you the confidence that your commercially valuable intellectual property is in the best hands.
t: +44 (0)20 7776 5300
t: +44 (0)117 945 1234
t: +44 (0)1223 420383
t: +44 (0)161 247 7722
For many months now, we have known that Brexit is likely to bring changes to IP rights in Europe. That changed on 7 September with the publication of the European Commission’s position paper on IP.
Estonia and Lithuania have ratified the UPC Agreement despite continuing uncertainty over UK and German ratifications. The reasons for the challenge in the German Constitutional Court (as reported here) have now been made public.